Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Dietary Supplementation for Para-Athletes: A Systematic Review.Nutrients · 2021
   Pooled it
2. Tetrahydrocannabinol/cannabidiol in the treatment of restless legs syndrome.Journal of neurology · 2026
   Trial
3. The role of Sativex in robotic rehabilitation in individuals with multiple sclerosis: Rationale, study design, and methodology.Medicine · 2017
   Trial
4. The Pharmacological Activity of Non-Cannabinoid Phytochemicals inPlants (Basel, Switzerland) · 2026
   Review
5. Population pharmacokinetic modelling revealed large variability in oromucosal absorption of ΔBritish journal of clinical pharmacology · 2026
   Article
6. Exploring Cannabinoid Effects Using Zebrafish (International journal of molecular sciences · 2025
   Review
7. The Cannabinoid Pharmacology of Bone Healing: Developments in Fusion Medicine.Biomedicines · 2025
   Review
8. Recent HPLC-UV Approaches for Cannabinoid Analysis: From Extraction to Method Validation and Quantification Compliance.Pharmaceuticals (Basel, Switzerland) · 2025
   Review
9. Decoding the Therapeutic Potential of Cannabis and Cannabinoids in Neurological Disorders.Current pharmaceutical design · 2025
   Review
10. Inflammation and cancer: friend or foe?Frontiers in pharmacology · 2024
    Review
11. Nanocarriers for Cannabinoid Delivery: Enhancing Therapeutic Potential.Recent advances in drug delivery and formulation · 2024
    Review
12. Synthetic Pathways to Non-Psychotropic Phytocannabinoids as Promising Molecules to Develop Novel Antibiotics: A Review.Pharmaceutics · 2023
    Review
13. Beyond Pain Relief: A Review on Cannabidiol Potential in Medical Therapies.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
14. Impact of the Cannabinoid System in Alzheimer's Disease.Current neuropharmacology · 2023
    Review
15. Should oncologists trust cannabinoids?Frontiers in pharmacology · 2023
    Review
16. Adjunctive Management of Opioid Withdrawal with the Nonopioid Medication Cannabidiol.Cannabis and cannabinoid research · 2022
    Review
17. Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer's disease symptoms: a case report.Journal of medical case reports · 2022
    Article
18. Cannabinoids: Therapeutic Use in Clinical Practice.International journal of molecular sciences · 2022
    Review
19. Considerations for Cannabinoids in Perioperative Care by Anesthesiologists.Journal of clinical medicine · 2022
    Review
20. Associated factors of potential drug-drug interactions and drug-food interactions in patients with multiple sclerosis.Therapeutic advances in chronic disease · 2022
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as